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Background Many HIV-infected patients on highly active antiretroviral therapy (HAART)
experience metabolic complications including dyslipidaemia and insulin resis-
tance, which may increase their coronary heart disease (CHD) risk. We
developed a prognostic model for CHD tailored to the changes in risk factors
observed in patients starting HAART.
Methods Data from five cohort studies (British Regional Heart Study, Caerphilly and
Speedwell Studies, Framingham Offspring Study, Whitehall II) on 13 100 men
aged 40–70 and 114 443 years of follow up were used. CHD was defined as
myocardial infarction or death from CHD. Model fit was assessed using the
Akaike Information Criterion; generalizability across cohorts was examined
using internal-external cross-validation.
Results A parametric model based on the Gompertz distribution generalized best.
Variables included in the model were systolic blood pressure, total cholesterol,
high-density lipoprotein cholesterol, triglyceride, glucose, diabetes mellitus, body
mass index and smoking status. Compared with patients not on HAART, the
estimated CHD hazard ratio (HR) for patients on HAART was 1.46 (95% CI
1.15–1.86) for moderate and 2.48 (95% CI 1.76–3.51) for severe metabolic
complications.
Conclusions The change in the risk of CHD in HIV-infected men starting HAART can be
estimated based on typical changes in risk factors, assuming that HRs estimated
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using data from non-infected men are applicable to HIV-infected men.
Based on this model the risk of CHD is likely to increase, but increases may
often be modest, and could be offset by lifestyle changes.
Keywords Highly active antiretroviral therapy, protease inhibitors, non-nucleoside reverse
transcriptase inhibitor, coronary heart disease, adverse effects, prognosis,
coronary risk factors
Introduction
The effectiveness of highly active antiretroviral therapy
(HAART) in preventing clinical progression of HIV-1 infection1,2
has shifted attention to its adverse effects.3,4 HAART is
associated with a lipodystrophy syndrome, which is character-
ized by loss of peripheral subcutaneous fat, accumulation of
visceral fat and metabolic complications, including hyper-
cholesterolaemia, hypertriglyceridaemia, insulin resistance,
impaired glucose tolerance and type 2 diabetes.3,5 These
metabolic changes are likely to increase the risk of coronary
heart disease (CHD) in patients starting HAART, but this
increase has not been well defined to date.
The estimation of changes in CHD risk is hampered by the
lack of a suitable comparator population: patients with HIV-1
infection who remain untreated have less advanced disease and
differ regarding body mass index (BMI), levels of exercise and
smoking. Comparisons with individuals not infected with HIV
is also problematic: there are important differences in the
prevalence of risk factors such as smoking between HIV-
infected and non-infected populations,6 and HIV-infection itself
may affect cardiovascular risk.7,8 Examining trends in CHD
with time on HAART avoids the choice of a comparator
population, but introduces the possibility of confounding
by changes in CHD risk factors associated with increased
well-being of patients.
The association of serum lipids and other risk factors with
CHD has been studied extensively in populations not known to
be infected with HIV.9–11 Changes in levels of CHD risk factors
associated with HAART are also well documented.6,8,12,13 In this
article we describe the development of a prognostic model,
based on five cardiovascular cohort studies of HIV-uninfected
men, which is tailored to the changes in cardiovascular risk
factors observed in patients starting HAART.
Materials and methods
Cardiovascular cohort studies
Criteria for selection of cardiovascular cohort studies included
the availability of individual person data, a comparable age
range, systematic assessment of CHD risk factors and long-term
follow up. Data from five cohorts, which are described in detail
elsewhere,14–18 were included. Briefly, The British Regional Heart
Study selected 7735 men aged 40–59 years at random from the
age-sex register of one general practice in each of 24 towns in
England, Wales and Scotland between January 1978 and June
1980 for a prospective study of cardiovascular disease.14 The
men were followed up for CHD outcomes using two-yearly
review of general practice records (including all hospital and
clinic correspondence), and additional questionnaires at 5 and
12–14 years after baseline examination, and were flagged with
the national mortality register. The Caerphilly Study recruited
2512 men aged 45–59 years between 1979 and 1983 from the
town of Caerphilly, South Wales and the adjacent villages.15
After the baseline examination the men have been seen five
times (phase I, II, III, IV and V) over the past 25 years and
have been followed up for mortality by flagging with the
national death register and for non-fatal CHD outcomes by
examining GP and hospital records. The Framingham Offspring
Study, based in Massachusetts, USA, included 5124 offspring
of 1644 spouse pairs from the original Framingham
cohort. At enrolment in 1972, the mean age was 36 years
(range 5–70 years) and 52% were female. CHD events were
reviewed by a panel of three investigating physicians using all
available pertinent records.16 The Speedwell Study is a prospective
cohort study of 2348 men aged between 45 and 63 years of age
at first examination who were recruited between 1979 and 1982
from the age-sex registers of 16 general practitioners working
from two neighbouring health centres in Bristol, England.
The protocol for this study was the same as for the Caerphilly
Study.15 The Whitehall II Study is a cohort of civil servants
established between 1985 and 1988 (phase 1). In total, 10 308
civil servants were examined: 6895 men (67%) and 3413
women (33%). CHD was assessed at five phases of data
collection using questionnaires, primary care and hospital
records. Follow-up for mortality uses flagging with the national
death register. The data used in this analysis were all measured
at phase 3 (1991–93) and incident CHD events were between
phase 3 and phase 5 (1997–99). Blood samples were taken
after fasting. Full details of the screening examinations are
reported elsewhere.17,18
Construction of prognostic model
Data from the five observational cohort studies were used to
construct a model for prediction of the risk of CHD. The
outcome was CHD events, defined as MI or death from CHD
(ICD-9 codes 410-414). Analyses were restricted to men for
the follow-up period during which they were aged 40–70 years.
Insufficient data were available on women. Men with prevalent
CHD, defined as a history of MI, angina (doctor diagnosis,
abnormal angiogram, abnormal exercise ECG or Rose Angina
questionnaire grade 1 or 2) or ECG abnormalities [Minnesota
codes 1 (Q), 4 (ST), 5 (T)] or 7-1 detected at baseline
examination, were excluded from the analyses. As baseline
measurements might predict less well over time, follow up
times were censored at 10 years after their first examination.
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The variables considered for inclusion in the model were
chosen to reflect known risk factors for CHD such as smoking
(never, ex-smoker, pipe or cigar, current cigarette smoker) and
particularly those potentially affected by the use of antiretro-
viral drugs such as systolic blood pressure (BP), total
cholesterol, HDL-cholesterol, triglyceride (log transformed
to give a normally distributed variable), glucose and diabetes
mellitus (modelled as three categories defined by measured
glucose with diagnosed diabetics included in the top category:
glucose 45.5,45.5 to 47,47 mmol/l or a diagnosis of diabetes)
and BMI. Baseline hazards were graphed for each cohort
separately using a non-parametric approach that estimates the
hazard as the first derivative of the smoothed Nelson–Aalen
cumulative survival curve. These showed that the baseline
hazard of CHD rose exponentially with age and differed
between the five cohorts. Therefore we used a parametric
model based on the Gompertz distribution (which has an
exponentially increasing baseline hazard), with age as the
underlying time variable.19 We also stratified on cohort, to
allow for the different rates of CHD in different settings.
Non-linear effects of continuous variables were examined by
comparing models with quadratic terms with linear models
using the Akaike Information Criterion (AIC).20 Non-
proportionality of hazards was examined using Schoenfeld
residuals. We examined all pairwise interactions between
covariates using Wald P-values and tested for changes in
covariate effects across 5-year age bands. Heterogeneity of
hazard ratios across the cohorts was examined using the I2
statistic.21 Candidate prognostic models with and without
interaction terms were assessed using AIC as a goodness of
fit criterion using first models stratified by cohort and secondly
models that pooled the data ignoring heterogeneity across risk
factors. Models were then assessed for generalizability across
the cohorts using internal–external cross-validation:22,23 four
cohorts are used to fit the prognostic model which is then
tested on the left-out cohort, rotating round the omitted cohort.
The test statistic is the difference in deviance between the
model fitted to the data from the omitted cohort with and
without re-estimation of parameters.23,24 All analyses were
performed in Stata (version 9.0, College Station, TX).
Applications of prognostic model
Based on a prospective study of 113 patients (98% men, mean
age 40 years) on protease inhibitor (PI) based HAART,25 we
defined typical risk factor profiles for HIV-infected men with
moderate or severe metabolic complications. We also generated
typical risk factor levels for men of the same age enrolled in the
cardiovascular cohort studies.26 We then estimated hazard
ratios comparing HIV-infected, non-smoking men with moder-
ate or severe metabolic abnormalities with an untreated
non-smoker and a smoker of the same age.
Results
A total of 13 100 men with 114 443 years of follow up were
available for analyses (Table 1). Median [interquartile range
(IQR)] age at baseline varied from 47 (43–51) years in the
Framingham Offspring study to 55 (51–59) years in the
Speedwell study. The proportion of participants with diabetes
Table 1 Baseline characteristics of subjects in CHD cohorts
British regional
heart study
Caerphilly
heart study
Framingham
offspring study
Speedwell
heart study
Whitehall
II study Overall
No.of subjects 4119 1825 934 1919 4303 13 100
No. CHD events 260 139 53 153 61 666
Follow-up period
Mean follow up (years) 9.5 9.4 9.6 9.2 7.3 8.7
Median (IQR)
Age at baseline (years) 50 (45–55) 52 (48–56) 47 (43–51) 55 (51–59) 49 (45–54) 50 (46–56)
Systolic BP (mmHg) 143 (131–157) 140 (126–150) 128 (120–140) 137 (124–153) 120 (112–129) 132 (120–147)
Total cholesterol (mmol/l) 6.2 (5.5–6.9) 5.6 (4.9–6.3) 5.5 (4.9–6.2) 5.8 (5.1–6.6) 6.4 (5.7–7.2) 6.0 (5.3–6.8)
HDL-cholesterol (mmol/l) 1.1 (1.0–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.0 (0.9–1.3) 1.3 (1.1–1.5) 1.2 (1.0–1.4)
Triglyceride (mmol/l) 1.7 (1.2–2.5) 1.6 (1.1–2.3) 1.2 (0.8–1.8) 1.3 (1.0–1.9) 1.3 (0.9–1.8) 1.4 (1.0–2.1)
Glucose (mmol/l) 5.4 (5.0–5.9) 4.8 (4.4–5.1) 5.8 (5.5–6.2) 4.8 (4.6–5.2) 5.2 (5.0–5.5) 5.2 (4.8–5.6)
BMI (kg/m2) 25.2 (23.3–27.1) 26.0 (23.8–28.1) 26.7 (24.8–29.0) 25.5 (23.5–27.6) 24.7 (23.0–26.7) 25.5 (23.4–27.4)
Percentage
Diabetes 1.1 1.4 4.4 1.6 0.8 1.4
Never smoked 22 17 15 16 47 28
Ex-smoker 27 28 29 36 38 32
Pipe or cigar smoker 10 11 13 10 3 8
Current cigarette smoker 41 44 43 38 12 32
*British Regional Heart Study is non-fasting glucose and median is for non-diabetics (N¼ 12920 out of total no. of subjects 13 100) as glucose was not always
measured for diabetics.
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was highest in the Framingham Offspring cohort while the
proportion of current smokers was much lower (12%) in the
Whitehall II cohort than in the other cohorts. There were 666
CHD events, of which 260 (39%) occurred in participants of the
British Regional Heart Study. Rates of CHD events varied from
1.5/1000 years at risk (95% CI 1.2–1.9) at age 40 to 7.5 (95% CI
4.6–12.2) at age 60.
Prognostic model
Table 2 shows crude hazard ratios (HR) for each covariate from
univariable models and also the mutually adjusted HR from
multivariable models fitted separately on each cohort, together
with the P-value for heterogeneity and the proportion of total
variance due to heterogeneity between studies. There was
evidence of heterogeneity in the effects of total cholesterol
and BMI. There was also evidence of between-cohort differ-
ences in underlying hazard of CHD. Figure 1 shows, for each
cohort, the cumulative proportions of men who had experi-
enced a CHD event according to age from Kaplan–Meier
survival curves. Rates of CHD were very similar in the British
Regional Heart Study and the Framingham, Caerphilly
and Speedwell studies, but were lower in the Whitehall II
study, possibly because it is an occupational cohort rather
than a community-based cohort. The curve for Speedwell is
displaced along the age axis reflecting the older age at
recruitment in this study.
Pooled HRs were derived using fixed-effects and random-
effects meta-analysis. In general, HRs from meta-analysis
were similar to those from the model using pooled data,
with the exception of smoking and diabetes. For smoking
and diabetes, the HR from the pooled data were somewhat
Table 2 Crude and mutually adjusted hazard ratios (HRs) for prognostic factors for CHD from Gompertz survival models fitted separately on each
cohort with P-values for test of heterogeneity and percentage of total variation due to heterogeneity between studies (I2)
British
regional heart
study
Caerphilly
heart study
Framingham
offspring study
Speedwell
heart study
Whitehall II
study
Heterogeneity
P-value I2
Crude HR (95% CI)
Systolic BP (per 20 mmHg) 1.45 (1.30–1.61) 1.39 (1.17–1.66) 1.07 (0.82–1.39) 1.35 (1.20–1.52) 1.57 (1.08–2.28) 0.20 33%
Total cholesterol (per mmol/l) 1.42 (1.28–1.59) 1.21 (1.06–1.39) 1.56 (1.26–1.92) 1.26 (1.11–1.43) 1.55 (1.25–1.92) 0.10 48%
HDL-cholesterol (per mmol/l) 0.37 (0.23–0.62) 0.47 (0.27–0.84) 0.38 (0.15–0.99) 0.52 (0.33–0.84) 0.12 (0.05–0.29) 0.004 74%
Triglyceride (per log(mmol/l)) 1.37 (1.10–1.70) 1.90 (1.43–2.54) 1.56 (1.06–2.28) 1.67 (1.21–2.29) 3.18 (2.06–4.91) 0.08 53%
Glucose 45.5 to <7 (mmol/l) 1.22 (0.94–1.58) 1.70 (1.06–2.74) 0.87 (0.48–1.58) 1.44 (0.90–2.31) 1.16 (0.64–2.09) 0.47 0%
Glucose 47 (mmol/l) or diabetes 1.71 (1.15–2.55) 2.09 (1.02–4.29) 1.20 (0.47–3.10) 2.28 (1.11–4.65) 3.54 (1.10–11.45) 0.70 0%
BMI (per kg/m2) 1.18 (0.98–1.42) 1.36 (1.09–1.70) 1.53 (1.06–2.21) 1.18 (0.93–1.50) 2.09 (1.49–2.95) 0.12 45%
Ex-smoker 0.99 (0.65–1.50) 1.42 (0.70–2.87) 0.59 (0.18–1.94) 1.38 (0.79–2.41) 1.00 (0.57–1.77) 0.58 0%
Pipe or cigar smoker 1.21 (0.73–1.99) 2.76 (1.33–5.75) 0.97 (0.26–3.62) 1.64 (0.83–3.25) 1.22 (0.29–5.12) 0.61 0%
Current cigarette smoker 1.86 (1.31–2.66) 2.80 (1.49–5.26) 2.94 (1.15–7.47) 1.77 (1.03–3.06) 1.70 (0.84–3.44) 0.79 0%
Adjusted HR (95% CI)
Systolic BP (per 20 mmHg) 1.45 (1.29–1.62) 1.35 (1.13–1.62) 1.08 (0.80–1.45) 1.32 (1.17–1.49) 1.31 (0.88–1.95) 0.37 7%
Total cholesterol (per mmol/l) 1.49 (1.32–1.68) 1.15 (1.00–1.32) 1.73 (1.34–2.23) 1.19 (1.04–1.35) 1.50 (1.17–1.93) 0.007 72%
HDL-cholesterol (per mmol/l) 0.34 (0.19–0.60) 0.65 (0.37–1.15) 0.49 (0.17–1.41) 0.54 (0.33–0.89) 0.16 (0.05–0.51) 0.07 55%
Triglyceride (per log(mmol/l)) 0.72 (0.55–0.95) 1.37 (0.98–1.94) 0.79 (0.50–1.27) 1.14 (0.79–1.66) 1.05 (0.55–2.02) 0.07 53%
Glucose 45.5 to <7 (mmol/l) 1.16 (0.89–1.52) 1.55 (0.95–2.53) 0.63 (0.34–1.19) 1.18 (0.72–1.91) 0.95 (0.52–1.73) 0.15 40%
Glucose 47 (mmol/l) or diabetes 1.58 (1.06–2.37) 1.72 (0.82–3.60) 0.64 (0.23–1.80) 1.85 (0.89–3.83) 2.57 (0.77–8.57) 0.18 36%
BMI (per kg/m2) 0.95 (0.77–1.16) 1.18 (0.93–1.50) 1.89 (1.24–2.88) 0.96 (0.74–1.25) 1.42 (0.97–2.08) 0.03 52%
Ex-smoker 0.98 (0.65–1.48) 1.35 (0.67–2.73) 0.57 (0.17–1.88) 1.30 (0.74–2.28) 0.89 (0.50–1.58) 0.59 0%
Pipe or cigar smoker 1.28 (0.77–2.11) 2.79 (1.34–5.80) 1.07 (0.29–4.05) 1.41 (0.71–2.82) 1.18 (0.28–4.98) 0.71 0%
Current cigarette smoker 1.89 (1.32–2.70) 3.09 (1.63–5.82) 3.36 (1.31–8.64) 1.66 (0.96–2.88) 1.41 (0.69–2.89) 0.51 0%
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Figure 1 Percentage of men in each cohort who experienced a
coronary heart disease (CHD) event by a certain age, estimated
using Kaplan–Meier survival curves. BRHS¼British Regional Heart
Study
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higher than those from the meta-analyses, although
confidence intervals overlapped. No evidence of non-linear
effects was found for the continuous variables systolic BP,
BMI, total cholesterol, HDL-cholesterol and log triglyceride.
There was weak evidence of interaction between systolic
BP and smoking status (P¼ 0.15). The HR for systolic BP
was 1.35 (95% CI 1.26–1.45) in the model without interactions,
but varied from 1.26 (1.14–1.39) for current smokers to
1.51 (1.33–1.71) for ex-smokers in the model with interactions.
There was some evidence of an interaction between systolic
BP and BMI (P¼ 0.02): increased SBP had a greater effect
in those with BMI 430. Tests of the proportional hazards
assumption showed that the HR for current smoker status
(P¼ 0.002) decreased with age and therefore we included
an interaction between smoking and age in candidate models.
The effect of being a current smoker was strongest at age
40 and diminished at older ages with nearly all CHD events
in the 40–44 age band occurring in smokers. Triglyceride
was correlated with cholesterol (correlation coefficient 0.36,
P< 0.0005), and the HR was close to 1 in the multivariable
model.
Models with interaction terms did not fit the data or
generalize across the cohorts substantially better than the
simpler model that did not include interaction terms (models
with interactions AIC 3909 to 3914 compared to AIC 3910
without interaction terms; the deviance difference was well
below the 5% w2 reference value for all models indicating no
substantial model misfit when applied to independent data).
We therefore chose the model without interactions as the
final prognostic model. The HR for the pooled data shown in
Table 3 are the HR from this model. Further details of
the prognostic model and the table of model coefficients are
given in the Appendix.
Application of prognostic model
Table 3 shows the typical risk factor profiles for two HIV-
infected men on antiretroviral therapy with moderate or severe
metabolic complications compared with a typical non-infected
man from the cardiovascular studies. The CHD HR for the HIV-
infected man compared with the control is 1.46 (95% CI
1.15–1.86) for moderate and 2.48 (1.76–3.51) for severe
metabolic complications, assuming all are non-smokers. For
comparison, the CHD HR for a smoker compared with a non-
smoker is 2.04 (1.61–2.57) and therefore the HR for an HIV
patient with severe abnormalities who is also a smoker is
approximately five compared with the control.
Calculations of the absolute risk of CHD may require
re-calibration of the model for the population in which it is
being used. We followed the method proposed by D’Agostino
et al.27 and parameterized the prognostic model by centering the
risk factors on explicitly stated reference values (‘mean
values’27) and estimated the constant in the linear predictor
that applies to a fixed absolute 10-year risk of CHD of 3% at
age 40. Examples and details of the reference values and
re-calibration procedure are given in the Appendix.
Discussion
Thanks to a collaborative effort involving five cardiovascular
cohort studies, a prognostic model that is tailored to the
changes in the cardiovascular risk profile typically observed
in HIV-infected patients initiating HAART could be developed.
Based on the changes in risk factors associated with
starting HAART that have been reported in published studies,
the model suggests that the CHD HR associated with
moderate metabolic abnormalities is about 1.5, less than that
due to smoking (2.0), while the HR associated with severe
Table 3 Estimated risk factor hazard ratios and examples of typical risk factor profiles of HIV-infected men with metabolic complications with their
predicted coronary risk relative to a typical non-infected man from the cardiovascular cohort studies
Non-smoking HIV-infected men with
metabolic complications Control men
Risk factor
Model
hazard ratio
Moderate
abnormalities
Severe
abnormalities Smoker Non-smoker
Age (years) 40 40 40 40
Systolic blood pressure (mmHg) 1.34 (1.25–1.44)a 120 120 120 120
BMI (kg/m2) 1.11 (0.98–1.25)b 25 25 23 23
Lipid factors (mmol/l)
Total cholesterol 1.31 (1.22–1.40) 5.7 6.2 5.3 5.3
HDL-cholesterol 0.46 (0.34–0.61) 0.97 0.85 1.1 1.1
Triglycerides 1.00 (0.85–1.18) 3.0 5.0 1.0 1.0
Impaired glucose tolerance 1.15 (0.95–1.39) Yes No No No
Diabetes 1.55 (1.16–2.08) No Yes No No
Ex-smoker 1.04 (0.81–1.35) No No No No
Pipe or cigar smoker 1.45 (1.06–1.98) No No No No
Current smoker 2.04 (1.61–2.57) No No Yes No
Hazard ratio (HR) for CHD from model 1.46 (1.15–1.86) 2.48 (1.76–3.51) 2.04 (1.61–2.57) 1(reference)
aHazard ratio for SBP is per 20 mmHg.
bHazard ratio for BMI is per 5 kg/m2.
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abnormalities is about 2.5, only slightly greater than the effect
of smoking. A major strength of this simple and generalizable
model is the inclusion of variables that are important in the
context of HAART-induced metabolic disturbances, BMI and
fasting blood glucose. The widely used Framingham or
PROCAM risk equations,28,29 for example, include the presence
or absence of diabetes, but not BMI or blood glucose.
The model should be useful to clinicians and patients and
help guide decisions on lifestyle changes and preventive drug
interventions.
Applicability of model
How applicable are our estimates to HIV-infected men?
It is well known that the accuracy of prognostic models tends
to decline from the data which was used to develop the model
to subsequent applications.30 We addressed this issue by
penalizing model complexity, and by choosing models that
generalized best to cohorts omitted from the estimation
procedure. Our database included individuals from four
community cohorts and one occupational cohort and two
countries. The model should therefore, in principle, be
transportable to populations other than those from which
the cohorts were drawn. Generalizability may also be compro-
mised if important independent predictors are omitted from
the model.31 We have included classical cardiovascular risk
factors but could not include newer factors,32 as no information
on these was collected in the participating cohort studies.
Further, we were not able to include measures of central
obesity (e.g. waist–hip ratio), since these were only available
in one of the cohorts. Waist–hip ratio is a stronger predictor
of CHD risk than BMI and therefore it would be preferable
to include waist–hip ratio.33 HIV-infected patients may
develop coagulation abnormalities such as increased levels of
fibrinogen, D-dimer, plasminogen activator inhibitor-1 and
tissue-type plasminogen activator antigen, or a deficiency
of protein S.34 Again, we were unable to consider these factors
in our model.
The wisdom, or otherwise, of extrapolating estimates of
coronary risk from prospective studies of non-HIV-infected
populations to HIV-infected patients with drug-induced meta-
bolic complications remains to be determined.35 Interestingly, a
collaborative study of more than 23 000 HIV-infected patients
from 11 prospective studies recently showed that CHD risk
was increased in patients starting HAART including a PI, bu not
with HAART based on a non-nucleoside reverse transcriptase
inhibitor (NNRTI): the relative rate per year of PI exposure was
1.16 (95% CI 1.10–1.23), while for NNRTI based HAART
it was 1.05 (0.98–1.13).36 We found similar results when
applying the prognostic model to men from the Swiss
HIV Cohort Study: predicted CHD rate ratios, compared to
before HAART was started, were 1.40 (CI 1.13–1.75) and 1.17
(0.95–1.47) for PI- and NNRTI-based HAART, respectively.37 A
study of 10-year CHD risk estimates obtained from the
Framingham risk equation found that HIV-infected patients
with fat redistribution had increased risk estimates, but
estimated risks were similar when compared to individuals
matched for age, sex and BMI from the Framingham
Offspring Study.38
Calibration and re-calibration
Poor calibration is a universal problem with generalizing
prognostic models to populations which differ substantially
from those used in fitting the models, either by ethnicity,
geography, calendar time, socioeconomic status, diet or any
other factor not included in the model which is likely to affect
risk of CHD. For example, the Framingham CHD risk functions
were based on data from white, middle-class North Americans
aged 30–74, with risk factor measurements taken over 30 years
ago. These risk functions have been re-calibrated for different
ethnic groups,27 and for different geographical regions, such as
European Mediterranean areas that have lower rates of CHD
than the US or Northern Europe.39 The method used to
re-calibrate the Framingham risk equation, which can also be
used for the risk equation presented here, assumes that HRs are
constant between cohorts. Whilst some studies have found HRs
to be similar across populations,29 others, such as the Diverse
Populations Collaboration that includes cohorts from North and
South America, Scandinavia and Southern Europe, have shown
heterogeneity in HRs.40
A simpler method for re-calibration of the Framingham
equation was used by Brindle et al.,41 who re-scaled the
equation for use with British men using data from the British
Regional Heart Study. Observed 10 year CHD mortality was
compared to the number of events predicted by the
Framingham model. The relative degree of overestimation was
similar at all levels of CHD risk and so the Framingham
equation could be re-scaled by dividing the calculated score for
each individual by the amount of over-prediction. The draw-
back with this method is that it does not take into account
differences in prevalence of risk factors in different populations.
This is an important factor in re-calibrating risk functions for
use with an HIV positive population as their risk of CHD is
likely to be higher than the risk for the HIV negative population
in the same region, due to higher smoking rates.6
Relative and absolute changes in CHD risk
Prognostic models can be used to estimate both the absolute
risk of CHD associated with given levels of CHD risk factors,
and the CHD HRs associated with given changes in the levels of
CHD risk factors. Here, we have focused on the HRs associated
with the metabolic abnormalities that have been reported for
men on HAART. For patients starting HAART, and their
physicians, it will be the absolute risk of CHD that will be of
primary importance in considering whether to initiate CHD
preventive medication such as statins. Such risks could
be estimated using the model presented here, based
on patients’ measured risk factor levels, both before and
during the first months and years after starting therapy. As
illustrated in Figure 1, age will be the most important
determinant of CHD risk.
Modelling of age
Part of the explanation for variation in the reported effect of
CHD risk factors in different populations might be differences
in age structure. The modelling of baseline age as a risk factor
along with other modifiable risk factors is problematic. CHD
risk is extremely low at ages less than 40 and then increases
exponentially with age. Therefore we chose to model the effect
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of age by including it in the baseline hazard, so that we
modelled the change in CHD risk with age, rather than
with time in study.19 This implies that subjects of the same
age are compared in assessing the effect of other risk factors,
and that it is possible to estimate the cumulative lifetime risk of
CHD rather than the risk restricted to the number of years of
follow up available in the cohorts. Levels of other risk
factors will change with age, and their relative effect on CHD
risk might also vary with age. We found some evidence that
the effect of smoking was age-dependent, with smoking having
a greater effect at younger ages. Finally, we excluded subjects
with existing CHD from the data used to fit the prognostic
model and from predictions using the model: the proportion of
such subjects will vary depending on the age structure of the
cohort so that the relevance of our model will decrease in older
age groups in whom the prevalence of existing CHD is greater.
Conclusions
In this article we have described a prognostic model for
estimating risk of CHD that has been tailored for use with
HIV-infected men aged 40–70 years by including risk factors
affected by antiretroviral therapy. The estimated increase in
CHD HR for patients starting HAART may be directly calculated
from the model, using estimated changes in risk factors due
to specific antiretroviral regimens. The model also enables the
quantification of absolute risk of CHD and, in conjunction
with a prognostic model for progression to AIDS or death,42,43
potentially allows physicians to assess the benefit and harm of
antiretroviral therapy in individual patients. The model requires
further development for application to HIV-infected women.
In general, the use of the model to estimate absolute risk
of CHD will require calibration to specific HIV-infected
populations. Calibration and validation of this model and
comparison of predictive accuracy with other models, such
as the Framingham or PROCAM risk scores, in collaborations
of HIV cohorts that have validated cardiovascular
endpoints such as the Data Collection on Adverse
Events of Anti-HIV Drugs (DAD) Study Group is the subject
of future work.
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Appendix
Calculation of hazard ratio for CHD from the
prognostic model
The Gompertz survival function is parameterized
SðtÞ ¼ expð1ðexp ðtÞ  1ÞÞ
where S(t) is the probability of survival free of CHD at time t
 ¼ expPi¼8i¼1 xii is the linear prediction, constant term
always takes the value one.
The CHD HR attributable to treatment with HAART may be
calculated from the prognostic model using assumed changes in
risk factors37 using the coefficients of the model given in
Table A1 below. To calculate the HR substitute the assumed
changes in risk factors (in the specified units) in the equation
for the linear predictor, l, omitting the intercept terms (i.e. the
constant X8) so  ¼Pi¼7i¼1 xii. The HR is then the exponen-
tiated linear predictor HR¼ exp(). For example, if it is
assumed that SBP increases by 5 mmHg, total cholesterol by
2 mmol/l and BMI by 1 kg/m2, then
 ¼ 0:294  5
20
 
þ ð0:267  2Þ þ 0:101  1
5
 
¼ 0:63
HR ¼ expð0:63Þ ¼ 1:9
95% confidence intervals may be calculated for HRs, but require
the variance/covariance matrix (further details available from
the authors).
Calculation of absolute risk of a CHD event from
the prognostic model
The constants in the model are calibrated for a population with
a base 10 year risk of CHD of 3% (or equivalently a 5 year risk
of 1.3%) at the reference values of the continuous risk factors
and the reference groups of the categorical variables, that
is, normal glucose and never smoked. To use the model as
it stands—subtract the reference values from the risk
factor values of a patient before substituting in the equation
of the model. The value of 3% was chosen to be similar to the
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Framingham estimate of 10 year risk of hard CHD (myocardial
infarction and CHD death) at these values of risk factors
and is approximately equivalent to 4% risk of CHD events
including angina. In Europe currently used versions of the
Framingham equation often include soft CHD endpoints,
whereas, in the US the Adult Treatment Panel III (ATP)
guidelines on the detection, evaluation and treatment of high
blood cholesterol in adults, only hard CHD endpoints are
considered. The ATP guidelines (available at http://www.nhlbi.
nih.gov/guidelines/cholesterol/index.htm) suggest that hard
CHD is between two-thirds and three-quarters of total
CHD events.
Example: Calculate 5 year risk of CHD for a man aged 50
with SBP¼ 145, cholesterol¼ 6, HDL¼ 1.1, triglyceride¼ 2,
BMI¼ 27, glucose¼ 6 and who is a current cigarette smoker.
xb ¼ 145  120
20
 
 0:294 þ ð6  5Þ  0:267 þ ð1:1  1Þ
 0:779 þ logð2Þ  0:003 þ 27  25
5
 
 0:101
þ ð1Þ  0:136 þ ð1Þ  0:712 þ ð1Þ  6:148 ¼ 4:705
l ¼ expðxbÞ ¼ expð4:705Þ ¼ 0:00905
The probability of surviving 5 years free of CHD event at age 50
is calculated as the probability of surviving to age 55
conditional on survival to age 50 (NB subtract the reference
age, 40, from these ages). The 5 year risk of CHD is then
5 year risk CHD¼ 1 {S(t¼ 10) S(t¼ 15)}
S(t)¼ exp(g1 (exp(gt) 1))
S(15)¼ exp(0.00905 (0.067)1
(exp (0.067 15) 1))¼ 0.791
S(10)¼ exp(0.00905 (0.067)1
(exp (0.067 10) 1))¼ 0.879
5 year risk¼ 0.879 0.791¼ 0.088
5 year risk of CHD is 8.8%
Calibration of model in a new population
We describe an example of recalibration of the model to a
population whose reference values are the same as presented in
Table A1 other than that mean SBP¼ 140 mmHg and mean
cholesterol¼ 6.5 mmol/l, and that there are 30% never smokers,
20% ex-smokers and 50% current smokers. The 10 year risk of
CHD at these reference values is equal to 5%.
Step 1: Calculate the difference in the linear predictor due to
the differences between the mean values in the new population
and the reference values of the risk factors:
Difference¼SBP (SBPmean SBPref)/
20þchol (cholmean cholref)þex-smoker (proportion
ex-smoker)þcurrent-smoker (proportion current-smoker)
Difference¼ 0.294 (140 120)/
20þ 0.267 (6.5 5)þ 0.044 (0.2)þ 0.712 (0.5)
Difference¼ 0.294þ 0.4005þ 0.0088þ 0.356¼ 1.0593
Step 2: using the known 10 year CHD risk at the mean
values of the risk factors in the new population, calculate l
from the following equation
SðtÞ ¼ expð1ðexp ðtÞ  1ÞÞ
Substituting t¼ 10, ¼ 0.067 and since risk¼ 0.05, S(10)¼ 0.95
S(10)¼ exp(l 0.0671 (exp (0.067 10) 1))
0.95¼ exp(l 0.0671 (exp (0.067 10) 1))
log(0.95)¼l 0.0671 (exp (0.067 10) 1)
¼ [0.067 log(0.95)]/(exp (0.067 10) 1)
¼0.0702 log(0.95)
¼ 0.0036
Step 3: Calculate the calibration constant in the linear
predictor (X8 in Table A1) using the values calculated in steps 1
and 2
l ¼ expðxbÞ
xb¼ log 
Differenceþ constant¼ log 
Constant¼ logDifference¼ log(0.0036)
 1.0593¼5.6268 1.0593¼6.6861
Table A1 Coefficients and standard errors of prognostic model with risk factor reference values for calibration
Covariate label Coefficient SE Reference value
Linear predictor b
Systolic BP(per 20 mmHG) X1 0.294 0.037 120 (divide by 20)
Total cholesterol (per mmol/l) X2 0.267 0.035 5
HDL-cholesterol (per mmol/l) X3 0.779 0.148 1
Log triglyceride [per log(mmol/l)] X4 0.003 0.084 0 (trig¼ 1 mmol/l)
Glucose 45.5 to 47 (mmol/l) X5a 0.136 0.097 Ref group glucose 45.5 mmol/l
Glucose 47 (mmol/l) or diabetes X5b 0.439 0.150
BMI (per 5 kg/m2) X6 0.101 0.062 25 (divide by 5)
Ex-smoker X7a 0.044 0.130 Ref group never smoker
Pipe or cigar smoker X7b 0.370 0.161
Current cigarette smoker X7c 0.712 0.087
Constant X8 6.148 0.225 3% 10 year CHD risk
Shape parameter c
Constant 0.067 0.007
Age t 40
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The model is now calibrated to the new population. The mean
values in the new population should be subtracted from patient
risk factor values (instead of subtracting the reference values
reported in Table A1) and the new value of the constant is used
in calculating the linear predictor. We have assumed that the
shape constant g is appropriate to the new population. In
principal it would be possible to re-calibrate this parameter too,
but this would require estimates of CHD risk at a number of
different ages at specified risk factor values in the new
population.
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